FMP
Lumos Pharma, Inc.
LUMO
NASDAQ
Inactive Equity
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
4.34 USD
0 (0%)
About
ceo
Mr. Richard J. Hawkins
sector
Healthcare
industry
Biotechnology
website
https://www.lumos-pharma.comexchange
NASDAQ
Description
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
CIK
0001126234
ISIN
US55028X1090
CUSIP
55028X109
Address
4200 Marathon Boulevard
Phone
512 215 2630
Country
US
Employee
30
IPO Date
Nov 11, 2011
Key Executives
